{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:37:23Z","timestamp":1783075043778,"version":"3.54.6"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Targeted therapies and checkpoint blockade therapy (CBT) have shown efficacy for patients with Hodgkin lymphoma (HL) in the relapsed and refractory (R\/R) setting, but once discontinued owing to progression or side effects, it is unclear how successful further therapies will be. Moreover, there are no data on optimal sequencing of these treatments with standard therapies and other novel agents. In a multicenter, retrospective analysis, we investigated whether exposure to CBT could sensitize HL to subsequent therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Seventeen centers across the U.S. and Canada retrospectively queried medical records for eligible patients. The primary aim was to evaluate the overall response rate (ORR) to post-CBT treatment using the Lugano criteria. Secondary aims included progression-free survival (PFS), duration of response, and overall survival (OS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighty-one patients were included. Seventy-two percent had stage III\u2013IV disease, and the population was heavily pretreated with a median of four therapies before CBT. Most patients (65%) discontinued CBT owing to progression. The ORR to post-CBT therapy was 62%, with a median PFS of 6.3 months and median OS of 21 months. Post-CBT treatment regimens consisted of chemotherapy (44%), targeted agents (19%), immunotherapy (15%), transplant conditioning (14%), chemotherapy\/targeted combination (7%), and clinical trials (1%). No significant difference in OS was found when stratified by post-CBT regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In a heavily pretreated R\/R HL population, CBT may sensitize patients to subsequent treatment, even after progression on CBT. Post-CBT regimen category did not impact OS. This may be a novel treatment strategy, which warrants further investigation in prospective clinical trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2020-0167","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T11:15:26Z","timestamp":1595934926000},"page":"878-885","source":"Crossref","is-referenced-by-count":43,"title":["Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy"],"prefix":"10.1093","volume":"25","author":[{"given":"Nicole A.","family":"Carreau","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology, Perlmutter Cancer Center at NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orrin","family":"Pail","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York University School of Medicine & Langone Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid","family":"Merryman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Spinner","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Herrera","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Tomassetti","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhakrishnan","family":"Ramchandren","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Tennessee Medical Center, Knoxville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad S.","family":"Hamid","sequence":"additional","affiliation":[{"name":"Department of Oncology, Karmanos Cancer Institute, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[{"name":"McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Santiago","sequence":"additional","affiliation":[{"name":"McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Wagner-Johnston","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Paul","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Bair","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Barta","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Nathan","sequence":"additional","affiliation":[{"name":"Rush University Medical Center, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"Division of Hematology, Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelyn","family":"Burkart","sequence":"additional","affiliation":[{"name":"Division of Hematology, Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallawi","family":"Torka","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"David","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Wei","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Lansigan","sequence":"additional","affiliation":[{"name":"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Emery","sequence":"additional","affiliation":[{"name":"Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Persky","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Arizona Cancer Center, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Godfrey","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Chavez","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhe","family":"Xia","sequence":"additional","affiliation":[{"name":"New York University School of Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea B.","family":"Troxel","sequence":"additional","affiliation":[{"name":"New York University School of Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Diefenbach","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Perlmutter Cancer Center at NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"2021122510554027000_R1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11899-014-0220-7","article-title":"Relapsed Hodgkin lymphoma: Management strategies","volume":"9","author":"Montanari","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"2021122510554027000_R2","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122510554027000_R3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.5045\/br.2017.52.4.243","article-title":"Brentuximab vedotin: Clinical updates and practical guidance","volume":"52","author":"Yi","year":"2017","journal-title":"Blood Res"},{"key":"2021122510554027000_R4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3324\/haematol.2016.150656","article-title":"The emerging role of immune checkpoint inhibition in malignant lymphoma","volume":"102","author":"Hude","year":"2017","journal-title":"Haematologica"},{"key":"2021122510554027000_R5","first-page":"914","article-title":"Checkpoint inhibition in Hodgkin lymphoma: Saving the best for last?","volume":"30","author":"Lin","year":"2016","journal-title":"Oncology (Williston Park)"},{"key":"2021122510554027000_R6","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25154","article-title":"Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers","author":"Rossi","year":"2018","journal-title":"Am J Hematol"},{"key":"2021122510554027000_R7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jtho.2017.10.011","article-title":"Increased response rates to salvage chemotherapy administered after PD-1\/PD-L1 inhibitors in patients with non-small cell lung cancer","volume":"13","author":"Park","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"suppl 15","key":"2021122510554027000_R8","article-title":"Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer","volume":"35","author":"Leger","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122510554027000_R9","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16756","article-title":"Checkpoint blockade treatment sensitises relapsed\/refractory non-Hodgkin lymphoma to subsequent therapy","author":"Carreau","year":"2020","journal-title":"Br J Haematol"},{"key":"2021122510554027000_R10","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16854","article-title":"Is it time to rethink checkpoint blockade therapy in non-Hodgkin lymphoma?","author":"Phillips","year":"2020","journal-title":"Br J Haematol"},{"key":"2021122510554027000_R11","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122510554027000_R12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1023\/A:1009635201363","article-title":"Rank tests for matched survival data","volume":"5","author":"Jung","year":"1999","journal-title":"Lifetime Data Anal"},{"key":"2021122510554027000_R13","first-page":"115","volume-title":"Nonparametric Statistical Methods","author":"Hollander","year":"1973"},{"key":"2021122510554027000_R14","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","article-title":"Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi","volume":"34","author":"Merli","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122510554027000_R15","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122510554027000_R16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41409-019-0640-z","article-title":"Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment","volume":"55","author":"Rivas","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"2021122510554027000_R17","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2017-09-772673","article-title":"Transplant strategies in relapsed\/refractory Hodgkin lymphoma","volume":"131","author":"Shah","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2021122510554027000_R18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hon.2589","article-title":"Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease","volume":"37","author":"LaCasce","year":"2019","journal-title":"Hematol Oncol"},{"key":"2021122510554027000_R19","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.bbmt.2013.09.018","article-title":"Simplified validated prognostic model for progression-free survival after autologous transplantation for Hodgkin lymphoma","volume":"19","author":"Hahn","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122510554027000_R20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/bloodadvances.2019000736","article-title":"Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT","volume":"4","author":"Badar","year":"2020","journal-title":"Blood Adv"},{"key":"2021122510554027000_R21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/hematology.2019000029","article-title":"Novel agents and immune invasion in Hodgkin lymphoma","volume":"2019","author":"Merryman","year":"2019","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2021122510554027000_R22","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00277-018-3283-z","article-title":"Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant","volume":"97","author":"Elshenawy","year":"2018","journal-title":"Ann Hematol"},{"key":"2021122510554027000_R23","volume-title":"Keytruda (pembrolizumab) injection. Prescribing information"},{"key":"2021122510554027000_R24","volume-title":"Opdivo (nivolumab) injection. Prescribing information. Bristol-Myers Squibb","year":"2018"},{"key":"2021122510554027000_R25","volume-title":"Yervoy (ipilimumab) injection. Prescribing information. Bristol-Myers Squibb","year":"2018"},{"issue":"suppl 4","key":"2021122510554027000_R26","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122510554027000_R27","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.4049\/jimmunol.1800275","article-title":"Chemotherapy combines effectively with anti\u2013PD-L1 treatment and can augment antitumor responses","volume":"201","author":"Cubas","year":"2018","journal-title":"J Immunol"},{"key":"2021122510554027000_R28","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918762094","article-title":"Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: Is this the beginning of the end for cancer?","volume":"10","author":"Lazzari","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"2021122510554027000_R29","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"2021122510554027000_R30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"2021122510554027000_R31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00262-012-1390-6","article-title":"Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer","volume":"62","author":"Ramakrishnan","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"2021122510554027000_R32","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/1535-7163.MCT-17-1091","article-title":"Impact of chemical-induced mutational load increase on immune checkpoint therapy in poorly responsive murine tumors","volume":"17","author":"Kuczynski","year":"2018","journal-title":"Mol Cancer Ther"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2020-0167","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2020-0167","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2020-0167","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/10\/878\/41921534\/oncolo_25_10_878.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/10\/878\/41921534\/oncolo_25_10_878.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:56:50Z","timestamp":1640429810000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/10\/878\/6443789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,8,28]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2020-0167","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10,1]]},"published":{"date-parts":[[2020,8,28]]}}}